司美格鲁肽治疗肥胖的早期轨迹与长期持续性:一项人群队列研究
结果显示180天累积停药率36.5%、365天达67.6%,阿拉伯人群、低社会经济地位和当前吸烟与停药相关,第90天剂量及早期减重反应可识别停药风险。
要点
- 司美格鲁肽治疗肥胖的停药常见,365天累积停药率达67.6%。
- 第90天仍用0.25mg较1.0mg与后续停药风险升高相关(HR 1.88)。
- BMI降幅每少1个百分点,停药风险增加3%(HR 1.03)。
核心结论
- 司美格鲁肽治疗肥胖的停药常见,与社会人口学和早期治疗特征相关。
- 第90天剂量和早期减重反应可能有助于识别停药风险。
- 社会经济差异提示持续肥胖药物治疗可及性存在不平等。
研究设计与样本
- 停药定义为药物覆盖结束后间隔超过60天,采用多变量Cox模型包括第90天地标分析。
主要发现
- 阿拉伯人群部门(HR 1.65,95%CI 1.59–1.72)、低社会经济地位(HR 1.13,95%CI 1.09–1.17)和当前吸烟(HR 1.13,95%CI 1.09–1.17)与停药相关。
- BMI降幅每少1个百分点与停药风险增加3%相关(HR 1.03,95%CI 1.03–1.04)。
临床怎么用
- 第90天剂量和早期体重下降可辅助识别高停药风险患者。
- 关注低社会经济地位、阿拉伯人群和吸烟者的持续治疗支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims To assess semaglutide persistence in obesity management, identify factors associated with discontinuation and examine early tirzepatide adoption. Materials and Methods This retrospective cohort study used Clalit Health Services records of adults without diabetes initiating Wegovy between January and May 2025. Discontinuation was defined as a gap exceeding 60 days after medication coverage ended. Multivariable Cox models, including a Day-90 landmark analysis, assessed discontinuation. Tirzepatide adoption was evaluated following its December 2025 coverage introduction. Results Among 34 309 participants (67.0% women; mean age 44.6 years), cumulative discontinuation reached 36.5% at 180 days and 67.6% at 365 days. Arab population sector (hazard ratio [HR] 1.65, 95% CI 1.59–1.72), low socioeconomic status (HR 1.13, 95% CI 1.09–1.17) and current smoking (HR 1.13, 95% CI 1.09–1.17) were associated with discontinuation. In the day-90 landmark cohort (n = 28 218), remaining on 0.25 versus 1.0 mg was associated with subsequent discontinuation (HR 1.88, 95% CI 1.72–2.06), substantially attenuated after adjustment for early refill adherence. Each percentage-point smaller BMI reduction was associated with 3% higher discontinuation hazard (HR 1.03, 95% CI 1.03–1.04). Following tirzepatide availability, 2908 of 33 936 eligible participants (8.6%) initiated treatment over a median 3.1-month observation period. Adoption was associated with higher socioeconomic status and baseline BMI. Conclusions Semaglutide discontinuation was common and associated with sociodemographic and early treatment characteristics. Day-90 dose and early weight-loss response may help identify discontinuation risk. Socioeconomic differences suggest inequalities in sustained obesity pharmacotherapy access.
引用
- Diabetes, Obesity and Metabolism:Early Treatment Trajectory and Long‐Term Persistence to Semaglutide for Obesity: A Population‐Based Cohort Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。